Annual Report 2012
A Nonprofit Biotech Advancing New TB Vaccines For The World.

to explore our work this year

welcome
Thomas G Evans MD President and CEO of Biography

Thomas G. Evans, MD

President & CEO

Biography

2012 Annual Report
Letter from the CEO

Dear Colleagues,

Since its beginning, Aeras has dedicated itself to the idea that new, more effective tuberculosis vaccines will significantly alter the course of the global tuberculosis epidemic. When I took on the role of President and CEO earlier this year, I did it with confidence in the importance of our mission and a high level of enthusiasm for the scientific challenges that lay ahead.

We must delve deeper into understanding human immune response to TB, and rigorously work to diversify and advance a pipeline of next generation vaccine candidates.

These are critical steps to achieve the scientific breakthroughs we need to reach our goals, and this work can only be successful by working in close collaboration with a vast network of partners. Today, Aeras supports half of the vaccine candidates in the global pipeline. We are currently testing six vaccine candidates worldwide in nine clinical trials, and eight preclinical projects and platforms are in early stages of development.

In September, 2012, Aeras and our partners reached a major milestone when we concluded activities in the largest clinical trial to date, a late-stage trial of the TB vaccine candidate MVA85A as a booster vaccine for infants. The results, published in February, demonstrated that the vaccine candidate was safe, well tolerated and modestly immunogenic, but was not efficacious in preventing TB disease. While not the results we had hoped, the trial produced the most robust data generated in half-a-century and continues to provide crucial information in our efforts to advance the global portfolio.

Looking forward, we will continue to tackle scientific complexities in TB vaccine R&D by expanding our scientific collaborations and working in geographic regions where TB is endemic. This past year we joined with GlaxoSmithKline Vaccines to further the clinical development of one of the most advanced candidates in the global portfolio. In addition, the Bill & Melinda Gates Foundation reinforced its support of our vaccine manufacturing facilities, not only to push forward on TB vaccines, but also to assist other organizations in their efforts to develop vaccines for other neglected diseases. New, generous funding from the governments of Australia and the United Kingdom, announced in August, has also provided much needed global support for our efforts.

Our strategy moving forward will be to place greater emphasis on diversifying the pipeline of early-stage preclinical candidates and platforms, while we continue to scientifically advance candidates in the clinic. This approach, combined with a more rigorous global portfolio management system, aims to increase cost efficiencies and give us a greater chance at success.

I am looking forward to tackling these challenges with the Aeras team and our global partners. By hewing closely to these objectives and continuing to gather a broad base of international support and collaboration, we can fulfill our mission of advancing new tuberculosis vaccines for the world.

Here's to another great year‚

Signature Of Tom Evans

Tom Evans‚ MD ⋅ President & CEO

EXPOSED Film Series Shows the Urgent Need for New TB Vaccines

In March, Aeras launched EXPOSED, a four-part series of short films on the deadly global TB epidemic. The series focuses on current efforts to halt this airborne disease, which is growing more difficult to address, as well as the urgent movement to develop new tools to prevent it. By telling the stories of four inspiring individuals, interspersed with expert commentary from some of the world's top TB physicians, scientists, advocates and policymakers, EXPOSED brings viewers to the forefront of the race against tuberculosis.

financials

2012 Financials

  • Revenue Expand Details

  • Contributions from Foundations$ 40,776,763
  • Government Grants$ 6,074,292
  • Investment Income$ 207,115
  • Other Revenue$ 893,761
  • Total Revenue$ 47,951,931
100 100 100 100 100 100 100 100 100 100
85 13 1 1 u
85 13 1 1 u
85 13 1 1 u
85 13 1 1 u
85 13 1 1 u
85 13 1 1 u
85 13 1 1 u
85 13 1 1 u
85 13 1 1 u

$47
million

  • Expenses · Vaccine Research Programs

  • Vaccine Assessment$ 3,579,836
  • Vaccine Discovery$ 3,557,267
  • Technical Operations$ 13,265,329
  • Clinical$ 20,376,995
  • Total Vaccine Research Expenses$ 40,779,427
  • External Affairs$ 3,071,274
  • Total Program Services$ 43,850,701
  • Management and Administrative$ 5,943,178
  • Total Expenses$ 49,793,879
100 100 100 100 100 100 100 100 100 100
12 12 31 45 u
12 12 31 45 u
12 12 31 45 u
12 12 31 45 u
12 12 31 45 u
12 12 31 45 u
12 12 31 45 u
12 12 31 45 u
12 12 31 45 u
12 12 31 45 u
6 86 8 u
6 86 8 u
6 86 8 u
6 86 8 u
6 86 8 u
6 86 8 u
6 86 8 u
6 86 8 u

$49
million

  • Net Assets

  • Change in Net Assets$ 1,841,948
  • Net Assets · Beginning of Year$ 38,210,209
  • Net Assets · End of Year$ 36,368,261
100 100 100 100 100 100 100 100 100 100
5 95 u
5 95 u
5 95 u
5 95 u
5 95 u
5 95 u

$36
million

funders

Major Donors and R&D Partners

Aeras is only successful through collaborations and partnerships that help support our TB vaccine development efforts. Aeras gratefully acknowledges these important donors and R&D partners, along with the numerous other collaborators not listed here that help make our work possible:

  • Australian Aid
  • Bill Melinda
  • Rijksoverheid
  • UK AID
  • Crucell
  • GSK
  • IDRI
  • Statens Serum
  • Sanofi Pasteur
  • CDC
  • China National
  • EDCTP
  • FDA
  • National Institute
  • Okairos
  • The Research Council
  • Stop TB Partnership
  • TBVI
  • Wellcome Trust
  • SATVI
About Aeras

Aeras is a global nonprofit biotech advancing new TB vaccines for the world

View our 10-year timeline of progress


  •                               9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9 
                                  1
                                  9
                                  1
                                  9
                                  1         
                                  A
                             

    10
    years

    2013
    • Aeras receives a grant for AU$2.5 million from AusAID; data from first Phase IIb clinical trial for TB vaccines in infants, candidate MVA85A, is published in The Lancet; Aeras officially opens office in China, forming a partnership with China Center for Disease Control.

  •                               9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9 
                                  1
                                  9
                                  1                             
                                         
                                  A
                             

    9
    years

    2012
    • Aeras receives a grant from the Bill & Melinda Gates Foundation for up to $220 million; "TB Vaccines: A Strategic Blueprint for the Next Decade" is published in the journal Tuberculosis; Aeras partners with Tuberculosis Vaccine Initiative (TBVI), National Institute of Allergy and Infectious Diseases (NIAID), Infectious Disease Research Institute (IDRI), GlaxoSmithKline (GSK), and Chinese National Biotec Group (CNBG) – Aeras' first partnership in China.

  •                           9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9 
                                  1
                                 
                                 
                                  A
                             

    8
    years

    2010
    • The United States government shows its support to Aeras through grants from the National Institutes of Health (NIH) and the Food and Drug Administration (FDA).

  •                           9 
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                           
                                  A
                             

    6
    years

    2009
    • Aeras receives a grant from DFID for ₤10.5 million; Aeras launches an expanded TB vaccine process development and manufacturing facility in Rockville, MD; Aeras and partners the South African Tuberculosis Vaccine Initiative (SATVI), Oxford-Emergent Tuberculosis Consortium, and Wellcome Trust begin the first Phase IIb proof of concept trial in infants in South Africa.

  •                               9
                                  1
                                  9 
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                                     
                                  A
                             

    5
    years

    2008
    • In April of 2008, Aeras opens an office in Cape Town, South Africa; along with partners, announces two new candidate trials – GSK M72 Phase II in South Africa in collaboration with SATVI, and Crucell Ad35/AERAS-402 Phase IIb in Kenya.

  •                           9
                                  1
                                  9
                                  1
                                  9 
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                                     
                                  A
                             

    4
    years

    2007
    • The Bill and Melinda Gates Foundation awards Aeras a $200 million five-year grant.

  •                           9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9 
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1                             
                                                               
                                  A
                             

    3
    years

    2006
    • Aeras receives a grant from the Dutch government for €18.7 million; clinical trials begin for Crucell Ad35/AERAS-402.

  •                               9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9 
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                                                                             
                                  A
                             

    2
    years

    2005
    • Aeras joins in partnership with GSK and Statens Serum Institut; receives $4.5 million from Danida, the Danish development agency.

  •                               9
                                  1                             
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9 
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                           
                                  A
                             

    1
    year

    2004
    • The Bill & Melinda Gates Foundation grants $82.9 million to Aeras to develop new TB vaccines; Aeras begins its collaboration with Crucell to jointly develop Crucell Ad35/AERAS-402.

  •                               9
                                  1
                                  9
                                  1                             
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9 
                                  1
                                  9
                                  1
                                  9
                                  1
                                  9
                                  1
                                                                                                               
                                  A
                             

    1st
    year

    2003
    • On July 16, 2003, the Sequella Global Tuberculosis Foundation becomes Aeras Global TB Vaccine Foundation.
Global Pipeline Top Image

The Global Pipeline of TB Vaccine Candidates

Aeras and our global research and development partners play an integral role in developing approximately half of all TB vaccine candidates in clinical development around the world. There are also multiple collaborations underway for interesting leads at the preclinical stage of the pipeline.

Phase I
Ad5 Ag85A
MCMASTER CANSINO
MTBCAV
TBVI, ZARAGOZA, BIOFABRI
ID93 + GLA-SE
IDRI, Aeras sub heading aeras logo
Crucell Ad35 / MVA85A
Crucell, Oxford, Aeras sub heading aeras logo
Phase IIa
VPM 1002
Max Planck, VPM, TBVI, SII
H1 + IC31
SSi, TBVI, EDCTP, Intercell
RUTI
Archival Farma, S.L
H4 / AERAS-404 + IC31
SSI, Sanofi-pasteur, aeras, intercell sub heading aeras logo
H56 / AERAS-456 + IC31
SSI, Aeras, Intercell sub heading aeras logo
Crucell Ad35 / AERAS-402
Crucell, aeras sub heading aeras logo
Phase IIb
MVA85A / AERAS-456
Oxford, aeras sub heading aeras logo
M72 + AS01E
GSK, Aeras sub heading aeras logo
Phase III
M. Vaccae
Anhui longcom, china

Viral Vector

rBCG

ImmunotherapeuticMycobacterial - Whole Cell or Extract

Protein / Adjuvant

Attenuated M.Tb

AERAS Sponsored

Tuberculosis

Tuberculosis
Contagious and Airborne

Today, more than 2 billion people—almost one third of the world's population—are infected with TB, and 10 percent will become sick with the disease. Every year, 8.8 million people fall ill and 1.4 million die. Intensified efforts by the public health community to reduce disease burden have resulted in a more than 40 percent reduction in TB-related deaths over the past two decades. However, there are nearly a million more cases of TB in the world today than when the World Health Organization (WHO) declared TB a global emergency 20 years ago, with 7.8 million cases in 1990 and 8.7 million cases in 2011. Today, TB is second only to HIV/AIDS as the greatest killer worldwide due to a single infectious agent.

In addition, M. tuberculosis has evolved and become more challenging to cure, as evidenced by increasing cases of drug-resistant TB strains now present in almost all countries surveyed worldwide. While predominantly a disease of the poorest and most vulnerable, there is a clear risk of TB spreading even further internationally through migration and urbanization.

The costs of treating drug-resistant TB are staggering: more than $12,000 per multi-drug resistant (MDR-TB) patient in high-burden countries and as much as $500,000 in the United States. A recently released study found that in 2011, TB was costing the EU more than $700 million a year in treatment costs and another $7 billion a year in productivity losses.

New vaccines are essential to future TB elimination efforts.

  • 22 High Burden Countries

    From WHO Global TB Control Report 2012
    22 High Burden Countries

    These 22 countries account for 80% of the TB cases in the world.

  • 27 Countries with high levels of MDR-TB

    Globally, 3.7% of new cases and 20% of previously treated cases are estimated to have MDR-TB
    27 Countries with high levels of MDR-TB

    Globally, 3.7% of new cases and 20% of previously treated cases are estimated to have MDR-TB

  • 84 Countries with at least one case of XDR-TB

     
    84 Countries with at least one case of XDR-TB

    These countries have at least one documented case of XDR-TB

Board

Board of Directors

Learn More
  • R. Gordon Douglas, Jr, MD

    R. Gordon Douglas, Jr, MD

    Emeritus Professor of Medicine,
    Weill Cornell Medical College
    Board Chair

  • Barry Bloom, PhD

    Barry Bloom, PhD

    Distinguished Service Professor at Harvard University

  • Jim Connolly

    Jim Connolly

    Former President & CEO of Aeras

  • Hoosen (Jerry) Coovadia, MD

    Hoosen (Jerry) Coovadia, MD

    Director of Match,
    university of witwatersrand

  • Marja Esveld, MSc

    Marja Esveld, MSc

    senior advisor,
    research and innovation,
    ministry of health (the netherlands)

  • Thomas G. Evans, MD

    Thomas G. Evans, MD

    President and CEO of Aeras

  • Gustavo Gonzalez-Canali, MD

    Gustavo Gonzalez-Canali, MD

    Medecin des Hôpitaux
    - practicien hospitalier

  • Peter Barton Hutt

    Peter Barton Hutt

    Senior Counsel,
    Covington & Burling,
    and Lecturer, Harvard Law School

  • Wayne Pisano

    Wayne Pisano

    President and CEO of Vaxinnate

  • Regina Rabinovich, MD, MPH

    Regina Rabinovich, MD, MPH

    ExxonMobil Malaria Scholar in Residence, Harvard School of Public Health

  • Gerd Zettlmeissl, PhD

    Gerd Zettlmeissl, PhD

    Former CEO of Intercell AG

  • Lota S. Zoth, CPA

    Lota S. Zoth, CPA

    Former Senior VP
    and CFO of MedImmune, Inc.

Leadership

Senior Leadership Team

Learn More
  • Sharon Chan

    Sharon Chan

    Head, Aeras Asia

  • Thomas G. Evans, MD

    Thomas G. Evans, MD

    President and CEO

  • Gerard F. Fleury

    Gerard F. Fleury

    Chief Financial Officer

  • Sebastian Gelderbloem

    Sebastian Gelderbloem

    Head, Aeras Africa

  • Ann M. Ginsberg, MD, PhD

    Ann M. Ginsberg, MD, PhD

    Chief Medical Officer

  • Rita Khanna, PhD, JD

    Rita Khanna, PhD, JD

    General Counsel

  • Wendy Penry

    Wendy Penry

    Chief Human Resources Officer

  • Lewis Schrager, MD

    Lewis Schrager, MD

    Vice President
    Science Affairs

  • Kevin Sly

    Kevin Sly

    Vice President,
    Business & Corporate Development

  • Kari Stoever

    Kari Stoever

    Vice President,
    External Affairs

  • Dereck Tait, MB, ChB

    Dereck Tait, MB, ChB

    Director,
    Clinical Development South Africa

  • Eric Tsao, PhD

    Eric Tsao, PhD

    Vice President,
    Technical Operations

  • Barry Walker, PhD

    Barry Walker, PhD

    Senior Director,
    Preclinical Development

final
Go to Aeras.org